Quick summary
KPV is a naturally occurring anti-inflammatory tripeptide from alpha-MSH that inhibits NF-kB signaling at nanomolar concentrations. Unusually for a peptide, it shows oral bioavailability and has demonstrated potent effects in inflammatory bowel disease models.
Overview
KPV is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). Despite being only three amino acids long, KPV retains the potent anti-inflammatory properties of the full α-MSH molecule without the melanogenic (tanning) or steroidogenic effects. It has shown promise in inflammatory bowel disease and general inflammation management.
Mechanism of action
KPV enters cells and directly interacts with inflammatory signaling pathways in the nucleus. It inhibits NF-κB activation by preventing the phosphorylation and degradation of IκBα, reducing the transcription of pro-inflammatory genes. It also reduces the expression of inflammatory cytokines (TNF-α, IL-6, IL-1β) and has antimicrobial properties. Unlike its parent molecule α-MSH, KPV does not activate melanocortin receptors at typical doses.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| anti-inflammatory / gut health | oral | 200–500 mcg | 1-2x daily | Can be taken orally (unusual for peptides). Also available as subcutaneous injection. 4-8 week cycles. |
| systemic inflammation | subcutaneous | 200–500 mcg | daily | Subcutaneous for systemic effects. Often combined with BPC-157 for gut protocols. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Studies demonstrate potent anti-inflammatory effects in colitis models (reduced colonic inflammation scores by 60-70%), skin inflammation, and arthritis models. Oral administration showed efficacy in IBD models — unusual for a peptide, suggesting GI stability or local action. PLA-nanoparticle formulations enhanced oral bioavailability. In vitro studies confirm NF-κB inhibition at nanomolar concentrations. No human clinical trials completed.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with KPV for synergistic effects.
Legal status
Not FDA-approved. Available as a research peptide. Not regulated as a drug due to its status as a naturally occurring tripeptide fragment.
Sourcing & access
Research compound
KPV is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone. Despite being only three amino acids, it retains the full anti-inflammatory properties of alpha-MSH without causing tanning or hormonal effects.
KPV enters cells and directly inhibits NF-kB activation by preventing the phosphorylation and degradation of IkBa. This reduces the transcription of pro-inflammatory genes and lowers production of TNF-alpha, IL-6, and IL-1beta.
Yes, KPV has shown oral efficacy in IBD models, which is unusual for a peptide. This suggests either GI stability or local action in the gut. PLA-nanoparticle formulations have been shown to further enhance oral bioavailability.
Studies demonstrate KPV reduced colonic inflammation scores by 60 to 70 percent in colitis models. It is often combined with BPC-157 in gut health protocols for complementary anti-inflammatory and tissue repair effects.
Oral protocols typically use 200 to 500 mcg once or twice daily. For systemic inflammation, subcutaneous injection of 200 to 500 mcg daily is used. Cycles of 4 to 8 weeks are common.
Research references
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationPubMed
- Melanocortin-derived tripeptide KPV has anti-inflammatory effects in human airway epithelial cellsPubMed
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptidesPubMed
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative ColitisPubMed
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine modelPubMed